FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.